Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine.
作者信息
Tahir Usman, Yeh Robert W
机构信息
Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
出版信息
J Thorac Dis. 2016 Oct;8(10):E1226-E1229. doi: 10.21037/jtd.2016.10.05.
Abstract
摘要
相似文献
1
Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine.
J Thorac Dis. 2016 Oct;8(10):E1226-E1229. doi: 10.21037/jtd.2016.10.05.
2
Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine.
Expert Rev Cardiovasc Ther. 2017 Sep;15(9):681-693. doi: 10.1080/14779072.2017.1362980. Epub 2017 Aug 9.
3
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2016 Sep 6;134(10):e156-78. doi: 10.1161/CIR.0000000000000405. Epub 2016 Mar 29.
4
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.
5
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence.
Eur Heart J. 2016 Jan 21;37(4):353-64. doi: 10.1093/eurheartj/ehv712.
6
Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):347-355. doi: 10.1177/1074248416683048. Epub 2016 Dec 21.
7
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.
8
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043. Epub 2013 Oct 23.
9
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
J Am Coll Cardiol. 2012 Oct 9;60(15):1340-8. doi: 10.1016/j.jacc.2012.06.043. Epub 2012 Sep 19.
10
Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study.
Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):303-311. doi: 10.1093/ehjqcco/qcw051.
引用本文的文献
1
Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.
Curr Atheroscler Rep. 2017 Nov 4;19(12):56. doi: 10.1007/s11883-017-0698-2.
本文引用的文献
1
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11.
2
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.
3
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29.
4
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.
5
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001.
6
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
J Am Heart Assoc. 2015 Dec 7;4(12):e002524. doi: 10.1161/JAHA.115.002524.
7
Reply: Analysis of Dual Antiplatelet Therapy.
J Am Coll Cardiol. 2015 Nov 3;66(18):2056. doi: 10.1016/j.jacc.2015.08.855.
8
Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.
J Am Coll Cardiol. 2015 Mar 24;65(11):1092-102. doi: 10.1016/j.jacc.2014.12.046.
9
Long-term use of ticagrelor in patients with prior myocardial infarction.
N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.
10
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.
Zotero 插件